What DIVERCHIM does

DIVERCHIM CDMO is a privately held French Contract Development and Manufacturing Organization (CDMO) headquartered in Roissy-en-France, near Paris-Charles de Gaulle airport, operating from a state-of-the-art 3,000 m² facility built in 2013. The company specializes in small-molecule drug substance development and GMP manufacturing of high-added-value Active Pharmaceutical Ingredients (APIs), with a strategic focus on low-volume, high-complexity products including drug candidate APIs, APIs for orphan drugs and rare diseases, radiopharmaceutical precursors, GMP excipients and linkers, as well as specialty chemicals such as non-natural amino-acids, peptides, polymers, nano-lipids, hydrogels, oligonucleotides, and nucleosides. Its proprietary Internal Vectorized Radiochemistry (IVR) platform — with 10 years of experience and 30 projects handled since 2016 — anchors its nuclear-medicine offering, complemented by qualified GMP peptide synthesis, lyophilization, and ISO 5 aliquoting services.

The company monetizes through project-based CDMO contracts spanning preclinical to commercial supply, supported by dedicated Project Managers, a stage-gate development process, and a quality system built on ICH Q7 with GMP certification since 2015 and FDA site registration since 2021. DIVERCHIM serves pharmaceutical and biotech companies, nuclear-medicine sponsors, and developers of orphan/rare-disease therapies, primarily in France and EMEA, with active U.S. market preparation evidenced by two FDA mock inspections conducted in 2024. In 2024, DIVERCHIM expanded into antisense oligonucleotide (ASO) therapeutics via the PickASO project, in partnership with THERANEXUS (commercial), INSERM (scientific), and BPI France (financial).

DIVERCHIM is structured as a société par actions simplifiée with €982,280 share capital, controlled by INTSEL CHIMOS as parent. The firm operates with 11–50 employees, a lean management team spanning QA/Regulatory, QC/Analytical Development, Project Management, Large-Scale Production, Purchasing, HSE, and Finance/HR, and pursues a boutique enterprise sales motion via direct B2B engagement, a professional website, LinkedIn presence, and participation in industry conferences such as SNMMI.

Name

DIVERCHIM

Legal name

DIVERCHIM CDMO

Website

https://diverchim.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

DIVERCHIM CDMO is a French boutique Contract Development and Manufacturing Organization specializing in small-batch GMP manufacturing of high-added-value small-molecule APIs, radiopharmaceutical precursors, peptides, and antisense oligonucleotides for pharmaceutical, biotech, and nuclear-medicine customers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Other Chemical and Allied Products Merchant Wholesalers (42469)

SIC

Medicinal Chemicals & Botanical Products (2833), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Small molecule APIs
• Radiopharmaceutical precursors
• Contract development manufacturing
• GMP peptide synthesis
• Antisense oligonucleotide manufacturing

Headquarters

HQ city

Roissy-en-france

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Contract Manufacturing Services: DIVERCHIM generates revenue through contract development and manufacturing services for small molecule APIs, radiopharmaceutical precursors, GMP excipients, and specialty chemicals. Services span from preclinical stage through commercial supply, with projects managed via dedicated Project Managers and stage-gate processes. Revenue is project-based and likely follows milestone-based billing tied to development phases.
2. GMP Manufacturing Scale-up: Revenue from scaling API production from gram-scale GMP to dozens of kilograms, serving both drug candidate APIs and orphan drug/rare disease API markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

DIVERCHIM operates as a boutique Small Molecule Drug Substance CDMO (Contract Development and Manufacturing Organization) that develops and manufactures high added-value Active Pharmaceutical Ingredients for pharmaceutical and biotech clients. Core offerings cover small molecule APIs (drug candidates and orphan/rare disease APIs), radiopharmaceutical precursors under the Internal Vectorized Radiochemistry (IVR) platform, GMP excipients, linkers, peptides, oligonucleotides (ASO), and related specialty chemicals, with services running from preclinical stage through commercial supply.

Product overview

DIVERCHIM is a Small Molecule Drug Substance CDMO offering a comprehensive portfolio of high added-value Active Ingredients and related services. The core product line includes Small Molecule APIs (drug candidates and rare disease APIs), Radiopharmaceutical Precursors, GMP Excipients and Buffers, and specialty chemicals (Non-Natural Amino-Acids, Peptides, Polymers, Nano-Lipids, Hydrogels, Oligonucleotides, Nucleosides). Special features include Internal Vectorized Radiochemistry (IVR) for GMP precursor manufacturing, GMP Peptide Synthesis with lyophilization capabilities, and Aliquoting Services. Services span from preclinical stage to commercial supply, supported by quality assurance and regulatory expertise.

Differentiator

Problem solved

Functional benefit

Brands

• Internal Vectorized Radiochemistry (IVR): GMP Precursors and excipients development and manufacturing for radiopharmaceuticals, with 10 years of experience and 30 projects handled since 2016.
• PickASO

Products and services

• Small Molecule APIs (Drug Candidates, Orphan Drugs/Rare Disease APIs, Advanced Intermediates) Contract development and manufacturing of high added-value Active Pharmaceutical Ingredients for pharmaceutical and biotech clients targeting drug candidates, orphan/rare disease APIs, and advanced intermediates (RSM). Services run from preclinical stage to commercial supply with flexible scale-up at the GMP facility in Roissy-en-France.
• Radiopharmaceutical Precursors (Internal Vectorized Radiochemistry – IVR) GMP-grade development and manufacturing of radiopharmaceutical precursors and excipients for nuclear medicine applications, with bulk lyophilization, solid/liquid aliquoting, and reference standards, performed in an ISO 5 environment for companies in diagnostics and therapy radiopharmaceuticals.
• PickASO – Antisense Oligonucleotide (ASO) CDMO Service Antisense oligonucleotide (ASO) development and manufacturing service targeting innovative therapies, including the autophagy-activating ASO programme developed in partnership with THERANEXUS, INSERM, and BPI France. Available for biotech and pharmaceutical clients requiring specialized oligonucleotide capabilities.
• GMP Peptide Synthesis Service Solid phase peptide synthesis with dedicated glass reactors, qualified equipment, bulk lyophilization, and solid/liquid aliquoting in ISO 5 environment for biotech and pharmaceutical clients requiring GMP-grade peptides.
• GMP Excipients, Buffers, and Linkers Manufacturing GMP-certified manufacturing of excipients and buffer solutions used in pharmaceutical manufacturing, including lyophilization and aliquoting services for products such as Gentisic Acid, DTPA, Ammonium acetate, EDDA, and Sodium ascorbate. Targets pharmaceutical and radiopharmaceutical manufacturers needing compliant excipients and linkers.
• Specialty Chemicals Manufacturing (Non-Natural Amino-Acids, Polymers, Nano-Lipids, Hydrogels, Nucleosides) Contract manufacturing of niche specialty chemicals used in advanced therapeutic applications, including non-natural amino-acids, polymers, nano-lipids and hydrogels as advanced delivery system materials, and nucleosides for biotech and pharmaceutical clients.
• Aliquoting Services (2R–50R vials) and Reference Standards Manual and automatic solid aliquoting plus liquid aliquoting for 2R–50R vials, reference standards, and standalone analytics performed in an ISO 5 environment to support radiopharmaceutical and pharmaceutical manufacturing clients.

Quantifiable outcome

• 30 projects delivered in Internal Vectorized Radiochemistry since 2016
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• THERANEXUScoreStrategic or Co-development Partner · 1 January 2024Commercial partner for the PickASO project launched in 2024 to develop an antisense oligonucleotide (ASO) for innovative therapy to activate autophagy. THERANEXUS serves as the commercial partner while DIVERCHIM handles development and manufacturing.
• INSERMcoreStrategic or Co-development Partner · 1 January 2024Scientific partner for the PickASO project (2024) focused on developing an antisense oligonucleotide therapy. INSERM provides scientific expertise and research capabilities for the autophagy-activating ASO therapy development.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Seqens: French specialty CDMO offering small molecule API development and manufacturing, custom synthesis, and advanced intermediates. Closely comparable to DIVERCHIM as a France-based API CDMO serving pharma and biotech customers across similar modalities.
• Carbogen Amcis: Swiss-headquartered CDMO specializing in small molecule APIs, including high-potency, chiral, and complex intermediates for pharmaceutical and biotech customers. Comparable to DIVERCHIM as a mid-sized, specialty small-molecule drug substance CDMO with similar scale and customer profile.
• Hovione: Portuguese CDMO with global operations focused on small molecule APIs, particle engineering, and complex chemistry for pharma and biotech. Matches DIVERCHIM in niche drug substance manufacturing, GMP scale-up capabilities, and customer-driven CDMO model.
• Curium Pharma: Global radiopharmaceutical CDMO with manufacturing of nuclear medicine products, precursors, and finished doses. Highly comparable to DIVERCHIM's IVR radiopharmaceutical precursor and excipients business, particularly for nuclear medicine sponsors.
• Novasep (Axplora): French-headquartered CDMO (now Axplora) with strong expertise in complex small molecule APIs, advanced intermediates, and purification. Direct geographic and capability overlap with DIVERCHIM, particularly around complex chemistry for orphan and rare disease programs.
• PETNET Solutions (Siemens Healthineers): PETNET Solutions operates a global network of PET radiopharma manufacturing centers and radiopharmaceutical precursor supply. Comparable to DIVERCHIM as a radiopharmaceutical precursor CDMO serving diagnostic imaging and nuclear medicine customers.

Broad incumbents

• EuroAPI: Paris-based API manufacturer (spun out of Sanofi) producing small molecule APIs, intermediates, and specialty ingredients at industrial scale. French peer with overlapping drug substance focus, though operating at much larger scale than DIVERCHIM.
• Aenova: European pharmaceutical CDMO with capabilities spanning solid dosage forms, sterile liquids, APIs, and specialty manufacturing. Overlaps DIVERCHIM's drug substance and small-scale API work within a much broader CDMO portfolio.
• PCI Pharma Services: Global CDMO providing drug substance, drug product, and packaging services across small molecules and biologics. Comparable to DIVERCHIM on the small molecule API side but offers integrated downstream services far beyond DIVERCHIM's drug substance focus.
• Corden Pharma: Larger international CDMO covering small molecule APIs, peptides, oligonucleotides, and injectables. Overlaps with DIVERCHIM across most modalities (peptides, ASOs, small molecules) but at significantly greater scale, serving as a broad incumbent benchmark for the boutique DIVERCHIM platform.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/diverchim

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DIVERCHIM